Navigation Links
Scientists discover a genetic switch that links animal growth and cancer

Laboratory discoveries by scientists at two universities may lead to new directions in cancer therapy drugs. The researchers have discovered that a genetic switch involved in growth and development of an animal is the same one used to prevent normal cells from becoming cancerous.

The findings are reported in the April 18 issue of Current Biology. Experiments were carried out by first author Masamitsu Fukuyama, a postdoctoral scientist working in the laboratories of Joel H. Rothman, a professor in the Department of Molecular, Cellular and Developmental Biology at the University of California, Santa Barbara, and Ann Rougvie, a professor in the Department of Genetics, Cell Biology, and Development at the University of Minnesota. Fukuyama is now an assistant professor at the University of Tokyo.

"The parallels between the control of development during the normal process of maturation and the control of cancer growth are striking," said Rothman. "We recognize that cancer cells in many ways simply mimic what normal cells do in a developing animal, only at an unfortunate time and place."

In life, there is a time to wait and a time to grow, Rothman explained. "Many creatures remain in a waiting state until conditions are right for growth. A tiny redwood, for example, can remain persistently arrested for years inside a seed. Only when the seed senses water will it sprout and initiate development into a mature tree. Many animals similarly halt their development until the environment is right for growth and development."

The process is the same with cells, the basic units of life. Many cells remain in a quiescent state, neither growing nor multiplying until they are triggered to do so by an environmental cue, such as a hormone or injury. Cells possess braking mechanisms that keep them in this quiescent state. When the brakes fail, cells that should be static start growing and dividing, leading to cancer. These brakes are proteins called tumor sup pressors.

Working with a tiny roundworm known as Caenorhabditis elegans, an important animal model in biomedical science, the researchers discovered that a tumor suppressor known as PTEN also functions to keep the animal in a waiting state by blocking cell growth when food is absent.

If these animals hatch from their eggs without any source of nutrition, they are able to remain in a perpetually young state for a long time without growing. When they eventually find food they start growing and maturing into adults. The researchers discovered that this juvenile-to-adult switch is controlled by PTEN. When the gene for PTEN is defective, the animals attempt to grow and become mature even when they have no food.

"The attempt of these animals to grow when they should not is not only analogous to the inappropriate growth and proliferation of cells during the formation of tumors in cancer, it also involves the same players," said Rothman. The research team found that PTEN functions with two other proteins –?known as protein kinases –?that are also involved in cancer progression.

This discovery means that other proteins that keep the brakes on growth might be found by looking for additional genes that keep these animals in an immature state.

"Now that we have information about the switch that keeps animals developmentally arrested, we can readily identify other genes involved in this process," said Rothman. Such genes might similarly be involved in the formation of cancers and could provide new therapeutic targets for intervention in cancer.

The current findings took about four years to discover. The worms used in the research develop quickly, growing from an egg to an adult in three days, as compared to mice, for example, which take several months. The similarities between the number and identity of genes in humans and worms allow researchers to extrapolate from worms to humans in their genetic research.


'"/>

Source:University of California - Santa Barbara


Related biology news :

1. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
2. Scientists Replicate Hepatitis C Virus in Laboratory
3. Scientists detect probable genetic cause of some Parkinsons disease cases
4. Scientists find missing enzyme for tuberculosis iron scavenging pathway
5. Scientists seek answers on what activates deadly anthrax spores
6. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
7. Scientists collaborate to assess health of global environment
8. Scientists decipher genome of fungus that can cause life-threatening infections
9. Scientists discover the cellular roots of graying hair
10. Scientists rid stem cell culture of key animal cells
11. Scientists develop new color-coded test for protein folding
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology: